102PD MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC): FROM PROOF-OF-CONCEPT TO PHASE III TRIAL (MAGRIT)

✍ Scribed by Passlick, B.; Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabreh, J.; Esteban, E.; Malinowski, W.; Jassem, J.; Lopez-Brea, M.; Debruyne, C.

• Book ID: 118574402
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 44 KB
• Volume: 64
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/s0169-5002(09)70225-9